19:42:44 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-06 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning MVIR 0.00 SEK
2024-05-07 Årsstämma 2024
2024-04-30 Kvartalsrapport 2024-Q1
2024-02-15 Bokslutskommuniké 2023
2023-12-01 Extra Bolagsstämma 2024
2023-10-27 Kvartalsrapport 2023-Q3
2023-08-18 Kvartalsrapport 2023-Q2
2023-05-25 Ordinarie utdelning MVIR 0.00 SEK
2023-05-24 Årsstämma 2023
2023-04-27 Kvartalsrapport 2023-Q1
2023-02-15 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-19 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning MVIR 0.00 SEK
2022-05-05 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-15 Bokslutskommuniké 2021
2021-11-03 Kvartalsrapport 2021-Q3
2021-08-19 Kvartalsrapport 2021-Q2
2021-05-06 Ordinarie utdelning MVIR 0.00 SEK
2021-05-05 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-03-11 Extra Bolagsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2021-01-13 Extra Bolagsstämma 2020
2020-11-10 Kvartalsrapport 2020-Q3
2020-08-20 Kvartalsrapport 2020-Q2
2020-05-06 Ordinarie utdelning MVIR 0.00 SEK
2020-05-05 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-13 Bokslutskommuniké 2019
2019-11-27 Kvartalsrapport 2019-Q3
2019-08-28 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning MVIR 0.00 SEK
2019-05-09 Årsstämma 2019
2019-05-03 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-25 Kvartalsrapport 2018-Q2
2018-05-04 Ordinarie utdelning MVIR 0.00 SEK
2018-05-03 Årsstämma 2018
2018-04-27 Kvartalsrapport 2018-Q1
2018-02-14 Bokslutskommuniké 2017
2017-10-26 Kvartalsrapport 2017-Q3
2017-07-25 Kvartalsrapport 2017-Q2
2017-05-04 Ordinarie utdelning MVIR 0.00 SEK
2017-05-03 Årsstämma 2017
2017-04-28 Kvartalsrapport 2017-Q1
2017-03-08 Kapitalmarknadsdag 2017
2017-02-17 Bokslutskommuniké 2016
2017-02-02 Extra Bolagsstämma 2017
2016-11-10 Kvartalsrapport 2016-Q3
2016-08-17 Kvartalsrapport 2016-Q2
2016-05-04 Ordinarie utdelning MVIR 0.00 SEK
2016-05-03 Årsstämma 2016
2016-04-28 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-20 Kvartalsrapport 2015-Q3
2015-08-20 Kvartalsrapport 2015-Q2
2015-05-06 Ordinarie utdelning MVIR 0.00 SEK
2015-05-05 Årsstämma 2015
2015-05-05 Kvartalsrapport 2015-Q1
2015-02-27 Bokslutskommuniké 2014
2014-11-20 Kvartalsrapport 2014-Q3
2014-11-20 Extra Bolagsstämma 2014
2014-10-16 Kapitalmarknadsdag 2014
2014-08-21 Kvartalsrapport 2014-Q2
2014-08-21 Analytiker möte 2014
2014-05-09 Ordinarie utdelning MVIR 0.00 SEK
2014-05-08 Kvartalsrapport 2014-Q1
2014-05-08 Årsstämma 2014
2014-02-24 Bokslutskommuniké 2013
2013-11-21 Kvartalsrapport 2013-Q3
2013-10-10 Kapitalmarknadsdag 2013
2013-08-22 Kvartalsrapport 2013-Q2
2013-05-07 Ordinarie utdelning MVIR 0.00 SEK
2013-05-06 Kvartalsrapport 2013-Q1
2013-05-06 Årsstämma 2013
2013-03-13 15-7 2013
2013-02-22 Bokslutskommuniké 2012
2012-11-20 Kvartalsrapport 2012-Q3
2012-11-19 Kvartalsrapport 2012-Q3
2012-08-23 Kvartalsrapport 2012-Q2
2012-05-11 Ordinarie utdelning MVIR 0.00 SEK
2012-05-10 Årsstämma 2012
2012-05-10 Kvartalsrapport 2012-Q1
2012-02-22 Bokslutskommuniké 2011
2011-11-15 Kapitalmarknadsdag 2011
2011-10-24 Kvartalsrapport 2011-Q3
2011-07-08 Kvartalsrapport 2011-Q2
2011-05-06 Ordinarie utdelning MVIR 0.00 SEK
2011-05-05 Kvartalsrapport 2011-Q1
2011-05-05 Extra Bolagsstämma 2011
2011-05-05 Årsstämma 2011
2011-02-22 Bokslutskommuniké 2010
2010-10-22 Kvartalsrapport 2010-Q3
2010-07-08 Kvartalsrapport 2010-Q2
2010-04-30 Ordinarie utdelning MVIR 0.00 SEK
2010-04-29 Kvartalsrapport 2010-Q1
2010-02-18 Bokslutskommuniké 2009
2009-10-21 Kvartalsrapport 2009-Q3
2009-07-09 Kvartalsrapport 2009-Q2
2009-04-24 Ordinarie utdelning MVIR 0.00 SEK
2009-04-23 Kvartalsrapport 2009-Q1
2009-04-23 Årsstämma 1

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Medivir är ett läkemedelsbolag. Bolaget utvecklar läkemedel med fokus på cancersjukdomar och övriga allvarliga sjukdomar. Bolaget satsar på indikationsområden där tillgängliga behandlingsmetoder är begränsade eller där de helt saknas. Samarbeten och partnerskap är en del av bolagets affärsmodell och läkemedelsutvecklingen såväl som kommersialiseringen bedrivs antingen i egen regi eller i partnerskap med övriga aktörer. Huvudkontoret ligger i Huddinge.
2022-04-28 08:30:00

Momentum in several areas, not least the development of our cutting-edge project fostroxacitabine bralpamide

January - March
Financial summary for the quarter

  • Net turnover amounted to SEK 0.5 (9.9) million.
  • The loss before interest, tax, depreciation and amortization (EBITDA) amounted to SEK -31.4 (-7.2) million. Basic and diluted earnings per share amounted to SEK -0.59 (-0.18) and SEK -0.59 (-0.18) respectively.
  • Cash flow from operating activities amounted to SEK -39.9 (-1.5) million.
  • Cash and cash equivalents at the end of the period amounted to SEK 180.8 (269.3) million.
Significant events during the quarter
  • In January, it was announced that the WHO had selected fostroxacitabine bralpamide as the official generic name for the patented candidate drug MIV-818, which is in clinical development in primary liver cancer.
  • Jens Lindberg assumed his position as CEO of Medivir on January 24, 2022.
  • On February 3, additional data from the phase I study with fostroxacitabine bralpamide were presented at the European Association for the Study of the Liver (EASL) Liver Cancer Summit.
  • In February, a subgroup analysis of Medivir's phase II study with MIV-711 for osteoarthritis was published, showing significantly reduced osteoarthritis-related pain.
 

Conference call for investors, analysts and the media
The Interim Report January - March 2022 will be presented by Medivir's CEO, Jens Lindberg.
 

Time: Thursday, April 28, 2022, at 15.00 (CET).
Phone numbers for participants from:
Sweden + 46 8  505 583 57
Europe +44 33 3300 9262
US +1 646 722 4902

The conference call will also be streamed via a link on the website: www.medivir.com

The presentation will be available on Medivir's website after completion of the conference.

CEO's message
I took on the role as CEO of Medivir at the end of January with confidence and enthusiasm. Medivir is going through an exciting transformation journey and today has a focused strategy with a clear priority for our cutting-edge project fostroxacitabine bralpamide (fostrox) while we create value through partnerships for our other projects. 2021 was an eventful year with clear momentum in several areas, not least in terms of development for fostrox. Our vision is to improve the lives of cancer patients through transformative drugs, and after my first months at work, I feel confident that we are well equipped to do just that. We have a unique "first-in-class" project in liver cancer, a dedicated and competent team and clear priorities, so it is with confidence that I look forward to an exciting 2022.

In January, our cutting-edge project MIV-818 received the official generic name fostroxacitabine bralpamide from the World Health Organization WHO, something we see as an important step towards a product for the treatment of HCC. Fostrox has the potential to become the first liver-targeted and orally administered drug that can help patients with various cancers of the liver. Its unique mechanism of action means that it does not directly compete with other treatment options but instead enables attractive combination treatments with other drug alternatives in hepatocellular carcinoma (HCC). Liver cancer is the third leading cause of cancer-related deaths worldwide and HCC is the most common form of cancer that arises in the liver. The effect of today's medications is often limited and mortality remains at a high level.

In December, the first patient with HCC was dosed in our ongoing phase 1b/2a combination study with fostrox, at one of our clinical trial centers in the UK. Fostrox is given in two different combinations in the study, either with Lenvima®, a tyrosine kinase inhibitor, or with Keytruda®, an anti-PD-1 checkpoint inhibitor. Lenvima® and Keytruda® (approved in the USA) are currently approved as monotherapy for the treatment of HCC. During Q1, we have focused on initiating additional clinical trial centers in Spain and South Korea. Just over 40% of the centers are based in South Korea, which is of great importance for the future development of fostrox in Asia.

Additional biomarker data from the proof-of-concept demonstrated by fostrox in the completed phase I study were presented on February 3 at the European Association for the Study of the Liver (EASL) Liver Cancer Summit in an e-poster titled "Liver biopsy biomarkers in a phase 1 study of the prodrug MIV-818 demonstrates proof-of-concept for cancer in the liver". These data confirm, among other things, that fostrox shows a tumor-selective effect in the liver by causing the desired DNA damage and cell death in tumor cells in the liver but not in normal or healthy liver cells.

In early November 2021, we announced that our collaboration partner, IGM Biosciences, Inc., had initiated a phase I clinical study in solid tumors with birinapant in combination with its own DR5 agonist antibody IGM-8444. IGM has also announced that the combination is completed without any limiting safety issues in the first dose group, and that recruitment in the next dose group is initiated. The licensing agreement with IGM can potentially provide milestone payments up to a total of approximately USD 350 million as well as tiered royalties up to "mid-teens"

The continued focus for our business development lies on our two clinical projects for partnerships, remetinostat, for different types of skin cancer, and MIV-711, for osteoarthritis. Both projects come with very robust data packages.

In 2021 the business development potential for remetinostat was significantly strengthened through the renegotiated multi-party agreement and additional positive data from investigator-initiated phase II studies. For MIV-711, which has the potential to become the first disease-modifying treatment for osteoarthritis, an article was published at the end of February this year in Clinical and Experimental Rheumatology 2022. The article shows that in the subgroup of patients with pain in only one knee in the phase IIa study with MIV-711, a statistically significant reduction in osteoarthritis-related pain was observed after treatment. This occurred in parallel with positive structural changes in the knee joint. These interesting results provide good guidance for further clinical trials with MIV-711.

Our business development opportunities are important, not least as they provide good conditions for progressing the clinical development program for our cutting-edge project, fostrox. Our goal is to develop an effective drug for liver cancer that makes a real difference for patients and for healthcare and thus also for our shareholders. I look forward to a continued eventful 2022.

Jens Lindberg
Chief Executive Officer
 
For further information, please contact
Magnus Christensen, CFO, +46 (0)8 5468 3100. E-mail: magnus.christensen@medivir.com
 

This report has not been subject to auditors' review.
The information was submitted for publication at 08.30 CET on April 28,